YAP1 and non-small cell lung carcinoma: Xu et al. demonstrated that a YAP/TAZ inhibitor reduced EGFR-TKI resistance in NSCLC with EGFR mutations (L858R/T790M) by downregulating YAP/TAZ activity and inhibiting the ERK1/2 pathway.